LSM12
Chr 17LSM12 homolog
Also known as: PNAS-135
Predicted to enable RNA binding activity. Located in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]
Clinical Summary— LSM12
⚡
Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.97). One damaged copy is likely sufficient to cause disease.
Some data sources returned errors (1)
ensembl: TimeoutError: The operation was aborted due to timeout
Population Genetics & Constraint
gnomAD v4 — loss-of-function & missense intolerance
LoF intolerant — likely haploinsufficient
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.27LOEUF
pLI 0.972
Z-score 3.08
OE 0.00 (0.00–0.27)
Highly LoF-intolerant (top ~10% of genes)
Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
1.89Z-score
OE missense 0.47 (0.37–0.60)
46 obs / 98.7 exp
Mild missense constraint
Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.00 (0.00–0.27)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.47 (0.37–0.60)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.04
0≤1.21.6
LoF obs/exp: 0 / 11.0Missense obs/exp: 46 / 98.7Syn Z: -0.20
ClinVar Variant Classifications
0 submitted variants in ClinVar
Protein Context — Lollipop Plot
LSM12 · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
OMIM — Genotype-Phenotype Relationships
1 OMIM entry
LSM12, S. CEREVISIAE, HOMOLOG OF; LSM12
MIM #611793 · *
External Resources
Links to major genomics databases and tools
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
LSM12-EPAC1 defines a neuroprotective pathway that sustains the nucleocytoplasmic RAN gradient.
Lee J et al.·PLoS Biol
2020
Identification of RNA-splicing factor Lsm12 as a novel tumor-associated gene and a potent biomarker in Oral Squamous Cell Carcinoma (OSCC).
Dong Y et al.·J Exp Clin Cancer Res
2022
Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey.
Sun P et al.·BMC Cancer
2020
Construction of a prognostic prediction model for concurrent radiotherapy in cervical cancer using GEO and TCGA databases with preliminary validation analysis.
Yang S et al.·PLoS One
2025Functional
Anti-HLA Antibodies Testing on Solid Phase: Comparative Evaluation of Different Kit Vendors Through Luminex Technology.
Minucci PB et al.·Exp Clin Transplant
2017
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Functional characterization of LSM12 as a driver in uveal melanoma oncogenesis.
Tang J et al.·Adv Ophthalmol Pract Res
2025Open AccessFunctional
LSM12 promotes the lung squamous cell carcinoma progression through mediating alternative splicing of ARRB1.
Wu L et al.·Commun Biol
2025Open Access
Retracted: Potential Prognosis and Diagnostic Value of AKT3, LSM12, MEF2C, and RAB30 in Exosomes in Colorectal Cancer on Spark Framework.
Healthcare Engineering JO.·J Healthc Eng
2023Open Access
Convergent activation of two-pore channels mediated by the NAADP-binding proteins JPT2 and LSM12.
Gunaratne GS et al.·Sci Signal
2023
Top 5 resultsSearch Europe PMC ↗
Full-Text Mentions
NLP-detected gene mentions in article bodies · via PubTator3
First description of the t(3;17)(q27;q21)/IGF2BP2::LSM12 translocation in marginal zone lymphoma
Diez-Feijóo R et al.·Blood Adv
2023
LSM12 facilitates the progression of colorectal cancer by activating the WNT/CTNNB1 signaling pathway
Zhuang Y et al.·Oncol Res
2023
Lsm12 is an NAADP receptor and a two-pore channel regulatory protein required for calcium mobilization from acidic organelles
Zhang J et al.·Nat Commun
2021
Identification of LSM Family Members as Novel Unfavorable Biomarkers in Hepatocellular Carcinoma
Zhuang H et al.·Front Oncol
2022
Top 5 full-text resultsSearch PubTator3 ↗
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
No active trials found for this gene.
Search ClinicalTrials.gov →External Resources
Links to major genomics databases and tools